Pathological overview of steatohepatitic hepatocellular carcinoma in a surgical series

被引:4
|
作者
Trapani, Loic [1 ,2 ]
Beaufrere, Aurelie [1 ,2 ,3 ]
Hobeika, Christian [4 ]
Codjia, Tatiana [3 ,5 ]
Albuquerque, Miguel [2 ,3 ]
Bouattour, Mohamed [3 ,6 ]
Lesurtel, Mickael [1 ,5 ]
Cauchy, Francois [3 ]
Paradis, Valerie [1 ,2 ,3 ]
机构
[1] Univ Paris Cite, Paris, France
[2] Beaujon Hosp, AP HP Nord, Dept Pathol, FHU MOSAIC, Clichy, France
[3] INSERM, UMR 1149, Ctr Rech Inflammat, Paris, France
[4] Hop La Pitie Salpetriere, AP HP, Dept HPB & Digest Surg, Paris, France
[5] Beaujon Hosp, AP HP Nord, Dept HPB Surg, Clichy, France
[6] Beaujon Hosp, AP HP Nord, Dept Hepatol, Clichy, France
关键词
ballooning; metabolic syndrome; pathological definition; prognosis; steatohepatitic hepatocellular carcinoma; FATTY LIVER; NONALCOHOLIC STEATOHEPATITIS; SCORING SYSTEM; RISK-FACTORS; VARIANT; ALGORITHM; FEATURES;
D O I
10.1111/his.14941
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
AimsAccording to the last WHO classification, steatohepatitic hepatocellular carcinoma (SH-HCC) is recognized as a distinct HCC subtype, even though a consensual definition is still lacking. The objectives of the study were to carefully describe the morphological features of SH-HCC and evaluate its impact on prognosis. Methods and resultsWe conducted a single-centre retrospective study including 297 surgically resected HCC. Pathological features including SH criteria (steatosis, ballooning, Mallory-Denk bodies, fibrosis, and inflammation) were assessed. SH-HCC was defined by the presence of at least four of the five SH criteria and the SH component represented >50% of the tumour area. According to this definition, 39 (13%) HCC cases corresponded to SH-HCC and 30 cases (10%) corresponded to HCC with an SH component (<50%). SH criteria in SH-HCC and non-SH-HCC were distributed as follows: ballooning (100% versus 11%), fibrosis (100% versus 81%), inflammation (100% versus 67%), steatosis (92% versus 8%), and Mallory-Denk bodies (74% versus 3%). Inflammation markers (c-reactive protein [CRP] and serum amyloid A [SAA]) were significantly more expressed in SH-HCC compared to non-SH-HCC (82% versus 14%, P = <0.001). Five-year recurrence-free survival (RFS) and 5-year overall survival (OS) were similar for SH-HCC and non-SH-HCC (P = 0.413 and P = 0.866, respectively). The percentage of SH component does not impact OS and RFS. ConclusionWe confirm in a large cohort the relatively high prevalence (13%) of SH-HCC. Ballooning is the most specific criteria for this subtype. The percentage of the SH component does not impact prognosis.
引用
收藏
页码:526 / 537
页数:12
相关论文
共 50 条
  • [1] Steatohepatitic hepatocellular carcinoma
    Torbenson, Michael S.
    Yeh, Mathew M.
    HEPATOMA RESEARCH, 2021, 7
  • [2] Clinicopathological Characteristics of Steatohepatitic Hepatocellular Carcinoma
    Taniai, Makiko
    Hashimoto, Etsuko
    Ikarashi, Yuichi
    Kodama, Kazuhisa
    Kogiso, Tomomi
    Torii, Nobuyuki
    Tokushige, Katsutoshi
    HEPATOLOGY, 2016, 64 : 648A - 649A
  • [3] Hepatocellular carcinoma: a clinical and pathological overview
    Renne, Salvatore Lorenzo
    Sarcognato, Samantha
    Sacchi, Diana
    Guido, Maria
    Roncalli, Massimo
    Terracciano, Luigi
    Di Tommaso, Luca
    PATHOLOGICA, 2021, 113 (03) : 203 - 217
  • [4] Characteristics of steatohepatitic hepatocellular carcinoma in a series of predominantly virus-related cirrhosis
    Aykutlu, U.
    Uguz, A.
    Unalp, O.
    Nart, D.
    Karasu, Z.
    Sozbilen, M.
    Yilmaz, F.
    VIRCHOWS ARCHIV, 2013, 463 (02) : 287 - 287
  • [5] Clinicopathological assessment of steatohepatitic hepatocellular carcinoma
    Yamaoka, Kenji
    Saitoh, Satoshi
    Kinowaki, Keiichi
    Fujiyama, Shunichiro
    Kawamura, Yusuke
    Sezaki, Hitomi
    Hosaka, Tetsuya
    Akuta, Norio
    Kobayashi, Masahiro
    Suzuki, Fumitaka
    Suzuki, Yoshiyuki
    Arase, Yasuji
    Ikeda, Kenji
    Fukusato, Toshio
    Kumada, Hiromitsu
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2022, 46 (08)
  • [6] Steatohepatitic hepatocellular Carcinoma:A new approach to classifying morphological subtypes of hepatocellular carcinoma
    Soon, Gwyneth S. T.
    Callea, Francesco
    Burt, Alastair D.
    Cook, Sam
    Terracciano, Luigi
    Ercan, Caner
    Dienes, Hans -Peter
    Goodman, Zachary D.
    Roberts, Eve A.
    Clouston, Andrew D.
    Gouw, Annette S. H.
    Kleiner, David E.
    Park, Young Nyun
    Chung, Taek
    Schirmacher, Peter
    Tiniakos, Dina
    Dimopoulou, Konstantina
    Weber, Achim
    Endhardt, Katharina
    Torbenson, Michael
    HUMAN PATHOLOGY, 2024, 149 : 55 - 65
  • [7] Steatohepatitic Hepatocellular Carcinoma: background liver disease and histology
    Benedict, Mark
    Mazer, Benjamin L.
    Jain, Anisha
    Celli, Romulo
    Taddei, Tamar
    Cha, Charles
    Jain, Dhanpat
    Zhang, Xuchen
    LABORATORY INVESTIGATION, 2018, 98 : 624 - 624
  • [8] Steatohepatitic Variant of Hepatocellular Carcinoma: A Focused Review
    Olofson, Andrea Morgan
    Gonzalo, David Hernandez
    Chang, Michael
    Liu, Xiuli
    GASTROENTEROLOGY RESEARCH, 2018, 11 (06) : 391 - 396
  • [9] Steatohepatitic hepatocellular carcinoma: a metabolic syndrome-associated carcinoma
    Jain, Deepali
    HISTOPATHOLOGY, 2015, 67 (02) : 267 - 267
  • [10] Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study
    Yeh, Matthew M.
    Liu, Yajuan
    Torbenson, Michael
    HUMAN PATHOLOGY, 2015, 46 (11) : 1769 - 1775